Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TFG |
| Gene Name: | TFG |
| Protein Full Name: | Protein TFG |
| Alias: | FLJ36137; TF6; TRK-fused gene; TRK-fused gene (NOTE: non-standard symbol and name); TRK-fused gene protein; TRKT3; TRKT3 oncogene |
| Mass (Da): | 43448 |
| Number AA: | 400 |
| UniProt ID: | Q92734 |
| Locus ID: | 10342 |
| COSMIC ID: | TFG |
| Gene location on chromosome: | 3q11-q12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19535 |
| Percent of cancer specimens with mutations: | 0.29 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | t(2;3)(p23;q21) with ALK in anaplastic large cell lymphoma; t(1;3)(q21;q11) with NTRK1 in thyroid papillary carcinoma; translocation with NR4A3 in extraskeletal myxoid chondrosarcoma |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | TFG is involved in multiple fusion oncoproteins. Translocations with NTRK1, a receptor tyrosine kinase, is involved in approximately 50% of thyroid papillary carcinomas. It may also participate in rearrangements resulting in anaplastic lymphoma and mixoid chondrosarcoma (translocations with ALK and NR4A3, respectively). It may be involved in the NF-kB signalling pathway. |